What NanoAlvand does

NanoAlvand is a knowledge-based pharmaceutical manufacturer established in 2011 and headquartered in Tehran, Iran, with a production facility in the Simindasht Industrial Area of Karaj. The company develops and manufactures highly potent generic pharmaceutical products across four therapeutic verticals — oncology, neurology, rheumatology, and other specialty categories (transplant immunosuppressants, anti-infectives, dermatology) — offering both injectable formulations (solution vials, lyophilized vials, pre-filled syringes) and oral formulations (tablets, micro-tablets, capsules). Its portfolio exceeds 126 finished dosage forms and includes complex generics such as Temozolomide, Venetoclax, Eribulin, Pomalidomide, and Ozanimod.

The company employs 501-1,000 personnel, with department-level breakdowns of more than 60 in R&D, more than 100 in Supply Chain, more than 70 in Quality Control, more than 50 in QA, more than 150 in Production, and more than 90 in Supporting Staff. NanoAlvand operates an enterprise field sales and business development motion targeting international markets, with exports to more than 12 destinations across 3 continents and more than 20 active international registration projects in progress. The business model combines pharmaceutical product sales, contract manufacturing, technology transfer, joint-venture manufacturing, and in-licensing arrangements, monetizing the portfolio through multiple channels and revenue streams. CEO Mehdi BabaSadeqian leads the company, which is privately held and operates without public market listing or venture funding.

Name

NanoAlvand

Legal name

NanoAlvand

Website

https://nanoalvand.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

501–1,000 employees

Short description

NanoAlvand is an Iranian knowledge-based pharmaceutical manufacturer founded in 2011, producing highly potent generic oncology, neurology, rheumatology, and specialty injectable and oral drugs for domestic and international markets across 12+ export destinations on 3 continents.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Pharmaceutical manufacturing
• Oncology medications
• Injectable formulations
• Oral solid dosage forms
• Contract manufacturing services

Headquarters

HQ city

Tehran

HQ country

Iran

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Manufactures and sells pharmaceutical products across oncology, neurology, rheumatology, and other therapeutic categories including immunosuppressants and anti-infectives.
2. Contract Manufacturing: Offers contract manufacturing services and technology transfer to international partners.
3. In-licensing: Engages in in-licensing arrangements for pharmaceutical products.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels3 records

Core offering

NanoAlvand manufactures and sells highly potent pharmaceutical finished dosage forms (FDFs) across oncology, neurology, rheumatology, transplant immunosuppression, anti-infective, and dermatology therapeutic areas. Products include injectable formulations (solution vials, lyophilized vials, pre-filled syringes) and oral formulations (tablets, micro-tablets, capsules). The company also offers contract manufacturing, technology transfer, joint-venture, and in-licensing services to international partners.

Product overview

NanoAlvand is a knowledge-based pharmaceutical company established in 2011, manufacturing highly potent pharmaceutical products for local and international markets. The company operates across four main therapeutic areas: Oncology, Neurology, Rheumatology, and Other Products. The Oncology portfolio includes over 60 products such as Ifoxa (Ifosfamide), Adriax (Doxorubicin), Tenoclax (Venetoclax), Vicrista (Vincristine), Alvotere (Docetaxel), Cabotax (Cabazitaxel), Alvinotec (Irinotecan), Alvopax (Paclitaxel), and Ty suna (Sunitinib). Neurology products include Danelvin (Fingolimod) and Zadiva (Dimethyl Fumarate) for multiple sclerosis treatment. Rheumatology offerings comprise Trexoma and Trexoma 2.5 (Methotrexate), Nupada (Upadacitinib), Intyma (Baricitinib), Rhofanib (Tofacitinib), and Clastoz (Zoledronic Acid). Other Products include Tedanix (Nintedanib) for pulmonary fibrosis, Xolitop (Ruxolitinib) for dermatology, Wellosia (Ozanimod), immunosuppressive products (Rolima, Suprotac, Merolic), and antifungal agents (Letocan, Pixana, Ricanza). The company offers both injectable formulations (solution vials, lyophilized vials, prefilled syringes) and oral formulations (tablets, micro-tablets, capsules).

Differentiator

Problem solved

Functional benefit

Products and services

• Ifoxa Ifosfamide vial formulation (1 g) indicated for treatment of patients with a wide range of malignant diseases.
• Adriax Doxorubicin hydrochloride vial formulation (10 mg/5 ml, 50 mg/25 ml) indicated for treatment of breast and lung cancers, malignant lymphomas, and leukemia.
• Tenoclax Venetoclax film-coated tablet (10 mg, 50 mg, 100 mg) indicated for treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).
• Vicrista Vincristine Sulfate injection (1 mg/ml) indicated for treatment of patients with cancers of the blood, breast, head and neck, or lung.
• Atranel Nelarabine injection (250 mg/50 ml) indicated for treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
• Ciplona Cisplatin injection (10 mg/10 ml, 50 mg/50 ml) indicated for treatment of testicular, ovary, bladder, head and neck epithelioma, small cell lung, advanced non-small cell lung, and cervical cancers.
• Parzino Olaparib indicated for treatment of patients with ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.
• Pomavid Pomalidomide capsule (1 mg, 2 mg, 3 mg, 4 mg) indicated for treatment of multiple myeloma and Kaposi sarcoma.
• Brescu Abemaciclib tablet (50 mg, 150 mg) indicated for treatment of patients with breast cancer.
• Winobin Vinorelbine vial and soft gelatin capsule (10 mg/1ml, 50 mg/5 ml, 20 mg, 30 mg) indicated for treatment of non-small cell lung cancer and advanced breast cancer.
• Tabinoz Decitabine injection (50 mg) indicated for treatment of acute myeloid leukemia (AML).
• Tenzala Enzalutamide indicated for treatment of prostate cancer.
• Suliba Bosutinib indicated for treatment of chronic myeloid leukemia (CML).
• Mertisso Osimertinib tablet (40 mg, 80 mg) indicated for treatment of non-small cell lung cancer in adults.
• Fiverna Fluorouracil injection (250 mg/5 ml, 1000 mg/20 ml) indicated for treatment of colorectal, gastric, pancreatic, esophageal, breast, and head and neck cancers.
• Relata Ruxolitinib tablet (5 mg, 10 mg, 15 mg, 20 mg) indicated for treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease (GvHD).
• Carbonatin Carboplatin injection (50 mg/5ml, 150 mg/15ml) indicated for treatment of ovarian carcinoma of epithelial origin and small cell lung carcinoma.
• Fularent Fulvestrant injection (250 mg/5ml) indicated for treatment of breast cancer.
• Fenosa Regorafenib tablet (40 mg) indicated for treatment of colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma.
• Filzoma Carfilzomib injection (60 mg) indicated for treatment of multiple myeloma.
• Tinopa Thiotepa injection (100 mg) indicated for preparation of patients for bone marrow transplantation.
• Reximed Methotrexate injection (1000 mg/10 ml) indicated for treatment of acute lymphocytic leukemia (ALL), non-Hodgkin's lymphomas, osteogenic sarcoma, breast cancer, head and neck cancer, choriocarcinoma trophoblastic, and advanced cancer of urinary bladder.
• Bronib Ibrutinib capsule (140 mg) indicated for treatment of mantle cell lymphoma, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease.
• Finota Everolimus indicated for treatment of hormone receptor-positive HER2-negative breast cancer, neuroendocrine tumors (NET), renal cell carcinoma (RCC), and tuberous sclerosis complex (TSC).
• Dasamed Dasatinib tablet (50 mg, 70 mg, 100 mg, 140 mg) indicated for treatment of acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML).
• Tiagem Gemcitabine injection (200 mg/2 ml, 1000 mg/10 ml) indicated for treatment of ovarian, breast, non-small cell lung, pancreatic, and bladder cancers.
• Amitzo Temozolomide hard gelatin capsule and vial (5 mg, 20 mg, 100 mg, 140 mg, 250 mg, 100 mg INJ) indicated for treatment of newly diagnosed glioblastoma multiforme and refractory anaplastic astrocytoma.
• Lotigna Nilotinib capsule (150 mg, 200 mg) indicated for treatment of chronic myeloid leukemia (CML).
• Dactoma Dactinomycin indicated for treatment of Wilms tumor, rhabdomyosarcoma, Ewing sarcoma, testicular cancer, gestational trophoblastic neoplasia, and solid malignancies.
• Milosun Busulfan injection (60 mg/10 ml) indicated for allogeneic hematopoietic progenitor cell transplantation.
• Sevara Sorafenib tablet (200 mg) indicated for treatment of hepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid carcinoma.
• Cybrin Palbociclib tablet (75 mg, 100 mg, 125 mg) indicated for treatment of breast cancer.
• Darbina Fludarabine Phosphate injection (50 mg/2 ml) indicated for treatment of B-cell chronic lymphocytic leukemia (CLL).
• Pralym Pralatrexate injection (20 mg/1 ml) indicated for treatment of peripheral T-cell lymphoma (PTCL).
• Zobis Zoledronic Acid injection (4 mg/5 ml) indicated for treatment of hypercalcemia of malignancy, multiple myeloma, and bone metastases from solid tumors.
• Xantomit Mitoxantrone injection (20 mg/10 ml) indicated for treatment of multiple sclerosis, prostate cancer, hepatocellular carcinoma, breast cancer, non-Hodgkin's lymphoma, and acute non-lymphocytic leukemia (ANLL).
• Alvocade Bortezomib injection (2.5 mg, 3.5 mg) indicated for treatment of multiple myeloma and mantle cell lymphoma.
• Bendanit Bendamustine HCL injection (25 mg, 100 mg) indicated for treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma.
• Lenoma Lenalidomide capsule (5 mg, 10 mg, 15 mg, 25 mg) indicated for treatment of multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma.
• Leudribine Cladribine injection (10 mg/10 ml, 10 mg/5 ml) indicated for treatment of hairy cell leukemia.
• Idanthra Idarubicin injection (5 mg/5 ml, 10 mg/10 ml, 20 mg/20 ml) indicated for treatment of acute myeloid leukemia (AML).
• Leukaza Azacitidine injection (100 mg) indicated for treatment of myelodysplastic syndrome.
• Neofor Plerixafor injection (24 mg/1.2 ml) indicated for stem cell transplantation.
• Xetabin Capecitabine tablet (500 mg) indicated for treatment of colorectal cancer and breast cancer.
• Xybrone Abiraterone Acetate tablet (250 mg, 500 mg) indicated for treatment of prostate cancer.
• Alvoxal Oxaliplatin injection (50 mg/10 ml, 100 mg/20 ml) indicated for treatment of colorectal cancer.
• Alvotere Docetaxel injection (20 mg/1 ml, 80 mg/4 ml, 160 mg/8 ml) indicated for treatment of breast, gastric, prostate, head & neck, and non-small cell lung cancers.
• Cabotax Cabazitaxel injection (60 mg/1.5 ml) indicated for treatment of prostate cancer.
• Alvopax Paclitaxel injection (30 mg/5 ml, 100 mg/16.7 ml, 150 mg/25 ml, 300 mg/50 ml) indicated for treatment of breast, ovarian, non-small cell lung cancer, and AIDS-related Kaposi's sarcoma.
• Alvinotec Irinotecan Hydrochloride injection (40 mg/2 ml, 100 mg/5 ml, 300 mg/15 ml) indicated for treatment of colorectal cancer.
• Alvopem Pemetrexed injection (100 mg, 500 mg) indicated for treatment of non-small cell lung cancer and malignant pleural mesothelioma.
• Tysuna Sunitinib capsule (12.5 mg, 25 mg, 50 mg) indicated for treatment of gastrointestinal stromal tumor, renal cell carcinoma, and pancreatic neuroendocrine tumors.
• Nibulin Eribulin Mesylate injection (1 mg/2 ml) indicated for treatment of patients with locally advanced or metastatic breast cancer and liposarcoma.
• Endoxyna Cyclophosphamide injection (500 mg/2.5 ml, 1000 mg/5 ml) indicated for treatment of patients with lymphomas, leukemias, multiple myeloma, mycosis fungoides, neuroblastoma, adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast.
• Etoraz Etoposide injection (100 mg/5 ml, 200 mg/10 ml) indicated for treatment of testicular cancer, small-cell lung cancer, blood cancer, tumors in the lymphatic system, and reproductive system cancers.
• Danelvin Fingolimod capsule (0.5 mg) indicated for treatment of multiple sclerosis.
• Zadiva Dimethyl fumarate hard gelatin capsule (120 mg, 240 mg) indicated for treatment of patients with relapsing forms of multiple sclerosis.
• Nupada Upadacitinib tablet (15 mg, 30 mg) indicated for treatment of patients with arthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease.
• Intyma Baricitinib tablet (2 mg, 4 mg) indicated for treatment of alopecia areata and rheumatoid arthritis.
• Trexoma Methotrexate prefilled syringe (7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg) indicated for treatment of rheumatoid arthritis and psoriasis.
• Trexoma 2.5 Methotrexate tablet (2.5 mg) indicated for treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriasis.
• Rhofanib Tofacitinib tablet (5 mg, 10 mg) indicated for treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
• Clastoz Zoledronic Acid infusion (5 mg/100 ml) indicated for treatment of osteoporosis and Paget disease.
• Tedanix Nintedanib soft gelatin capsule (100 mg, 150 mg) indicated for treatment of idiopathic pulmonary fibrosis (IPF), other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, and systemic sclerosis associated interstitial lung disease (SSc-ILD).
• Xolitop Ruxolitinib topical cream (1.5 g/100 g) indicated for treatment of non-segmental vitiligo with facial involvement and mild to moderate atopic dermatitis (eczema).
• Ricanza Voriconazole vial (200 mg) indicated for treatment of invasive aspergillosis, deep tissue candida infections, esophageal candidiasis, scedosporiosis, and fusariosis.
• Rolima Everolimus tablet (0.25 mg, 0.75 mg) indicated for treatment of kidney and liver transplant.
• Letocan Caspofungin Acetate injection (50 mg, 70 mg) indicated for treatment of candida infections, esophageal candidiasis, invasive aspergillosis, and febrile neutropenia.
• Suprotac Tacrolimus hard gelatin capsule and vial (0.5 mg, 1 mg, 5 mg, 5 mg/1 ml) indicated for treatment of heart, liver, kidney, and other organ transplants.
• Pixana Posaconazole injection (300 mg/16.7 ml) indicated for prophylaxis of invasive aspergillus and candida infections, and treatment of oropharyngeal candidiasis.
• Lyratan Macitentan tablet (10 mg) indicated for treatment of pulmonary arterial hypertension.
• Wellosia Ozanimod capsule (0.23 mg, 0.46 mg, 0.92 mg) indicated for treatment of multiple sclerosis and ulcerative colitis.
• Merolic Mycophenolic Acid enteric-coated tablet (360 mg) indicated for treatment of kidney transplant.

Quantifiable outcome

• More than 126 pharmaceutical products manufactured
• +2 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core.

• AryogencoreOthersPharmaceutical company partner featured on NanoAlvand's Our Partners page. Logo displayed as a partner company for potential collaboration.
• CinnagencoreOthersPharmaceutical company partner featured on NanoAlvand's Our Partners page. Logo displayed as a partner company for potential collaboration.
• Arvand PharmedcoreOthersPharmaceutical company partner featured on NanoAlvand's Our Partners page. Logo displayed as a partner company for potential collaboration.

Scale indicators5 records

Recent moves5 records

Expansion highlights6 records

Broad incumbents

• Apotex: Canadian-headquartered global generic manufacturer with a broad oncology and specialty injectables portfolio and significant emerging-market exports. Comparable as a larger-scale generic FDF manufacturer with injectable and oral capabilities.
• Cipla: Indian global pharmaceutical major with a major oncology and specialty generics franchise, including injectables and orals, with strong emerging-market presence. Comparable as a larger-scale generic oncology manufacturer serving similar therapeutic and geographic markets.

Regional players

• Julphar (Gulf Pharmaceutical Industries): UAE-headquartered pharmaceutical manufacturer with broad generic portfolio including oncology injectables and oral solids across MENA. Comparable on regional generic manufacturing scale and emerging-market export model.
• SPIMACO Addwaeih: Leading Saudi Arabian pharmaceutical manufacturer producing generics across oncology, CNS, and other therapeutic areas. Comparable in finished dosage form generics, MENA regional focus, and export-driven growth model.

Emerging players

• Natco Pharma: Indian specialty pharmaceutical company with a strong oncology generics franchise including complex injectables and oral oncology products. Comparable on focus on complex/high-barrier generics and emerging-market export strategy.
• Hetero Labs: Indian generic manufacturer with deep oncology portfolio spanning lyophilized injectables, pre-filled syringes, and oral oncology across emerging markets. Comparable on injectable oncology capabilities and CDMO/technology transfer business model.

Direct peers

• Tehran Pharma (TPICO): Established Iranian pharmaceutical manufacturer with a broad FDF portfolio including oncology and neurology products. Closely comparable to NanoAlvand on therapeutic breadth, domestic manufacturing focus, and export activity.
• Cinnagen: Iranian biopharmaceutical manufacturer and NanoAlvand's named partner, producing therapeutics including oncology and specialty medicines. Directly comparable as a domestic Iranian pharmaceutical peer with overlapping therapeutic areas and export ambitions.
• Darou Pakhsh Pharmaceutical Manufacturing Co. One of Iran's largest pharmaceutical manufacturers producing finished dosage forms across multiple therapeutic categories including oncology. Directly comparable in product mix, domestic scale, and Iran-headquartered FDF manufacturing model.
• Aryogen: Iranian specialty biopharma focused on biosimilars and complex therapeutics, listed as a NanoAlvand partner. Comparable in therapeutic scope (oncology, immunology), domestic market orientation, and export-driven growth model.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NanoAlvand